rs11573260 - PLA2G5

Magnitude 4.5 · 1 study on file

Reported associations

• Group IIA Secretory Phospholipase A2 and Incident Cardiovascular Disease: An Analysis from the JUPITER Trial - Unknown journal (n.d.) · Unknown authors · PubMed 31070471

  ABSTRACT: Objectives: Inflammation is a causal risk factor for cardiovascular disease (CVD). Group IIA secretory phospholipase A2 (sPLA2-IIA) plays an integral role in regulating vascular inflammation. While studies investigated sPLA2-IIA in secondary prevention, we prospectively evaluated sPLA2-IIA mass and genetic variants with CVD events in a primary prevention population with chronic inflammation. Approach and Results: The JUPITER trial (NCT00239681) randomized participants with LDLc <130 mg/dL and hsCRP ≥2 mg/L to high-intensity rosuvastatin vs placebo. Baseline and 1-year plasma sPLA2-IIA mass was measured (N=11,269 baseline; N=9,620 1-year). We also identified genetic variants influencing sPLA2-IIA using genome-wide association and examined them with CVD. 313 incident CVD events o

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.